Immunohistochemistry (IHC) Digital Breast Cancer Panel 4 in Dubai, UAE | 1500 AED | DHA Licensed Lab

Executive Summary & Core Metrics

99.9% Diagnostic Sensitivity via ISO-accredited digital IHC processing with quantitative AI-assisted image analysis for ER, PR, HER2, and Ki-67.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-accredited digital IHC processing with intra-observer variability below 2%.
Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks and biopsy slides with certified temperature-controlled transport.
Clinical Guidance: Telephonic post-test consultation with a DHA-licensed specialist to contextualize receptor status and treatment pathways.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The Immunohistochemistry (IHC) Digital Breast Cancer Panel 4 quantitatively evaluates estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and Ki-67 proliferation index using digital whole-slide imaging and automated image analysis algorithms. This molecular subtyping assay stratifies tumor biology into luminal A, luminal B, HER2-enriched, or triple-negative phenotypes, directly informing targeted therapy selection including anti-hormonal agents, anti-HER2 monoclonal antibodies, and chemotherapy regimens within UAE oncology practice.

Feature	Our Test (Digital IHC Panel 4)	Conventional IHC Breast Panel
Precision	Digital quantification with AI-assisted scoring; intra-observer variability <2%	Manual semi-quantitative scoring; variability up to 20%
Methodology	Immunohistochemistry with digital whole-slide imaging and automated image analysis	Immunohistochemistry with light microscopy, no digital component
Turnaround Time	Block: 5 days / Biopsy: 5 days / Large Complex: 7 days	Typically 7–10 working days, often without digitized reporting
Price	1500 AED	Varies (may exceed 1800 AED with add-on manual reads)

Physician Insight & Safety Protocols

"The IHC Digital Panel 4 delivers quantitative receptor profiling that must be interpreted within the full clinical context including tumor stage, grade, and patient history. A positive ER or PR result supports anti-hormonal therapy considerations, while HER2 amplification opens anti-HER2 targeted treatment options. Triple-negative phenotypes necessitate careful evaluation of chemotherapy and emerging immunotherapy clinical trials. These findings should always be reviewed with the treating oncologist before any treatment decisions are made."

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Advisory Notice

Do not discontinue any prescribed medication including tamoxifen, aromatase inhibitors, or chemotherapy without consulting your treating physician. This test serves as a prognostic and treatment guidance tool and does not replace standard surgical excision, staging procedures, or ongoing oncology management.

Exclusion Criteria & Safety Precautions

Exclusion Criteria: Unfixed tissue, decalcified specimens, or specimens with extensive necrosis may yield unreliable IHC results.
ER Red Flags: Sudden onset of severe pain at the biopsy site, active bleeding, or signs of infection such as fever, redness, or pus require immediate medical attention.
Clinical Urgency: This test is a prognostic and treatment guidance tool; it does not replace standard surgical excision or staging. Do not delay recommended cancer treatment while awaiting results.
Sample Integrity: Biopsy must be submitted as FFPE block or formalin-fixed tissue in 10% neutral buffered formalin. Provide a copy of the histopathology report, indicate biopsy site, and share complete clinical history with the laboratory.

Patient FAQ & Clinical Guidance

1. What is the cost and turnaround time for the IHC Digital Breast Panel 4 in the UAE?

A: The test costs 1500 AED and results are typically delivered within 5–7 working days. The panel provides comprehensive hormone receptor and HER2 status with Ki-67 proliferation index, enabling your oncologist to receive actionable digital data without unnecessary delay.

2. How should I prepare and submit the sample for this breast cancer panel?

A: No patient preparation is required. The biopsy or FFPE block must be submitted with a copy of the histopathology report and clinical history. Our Secure Medical Courier Solid Tissue Specimen Retrieval service collects the fixed tissue or paraffin block and transports it under controlled conditions to the laboratory for processing.

3. Is this digital IHC panel accepted by DHA and covered by insurance in the UAE?

A: Yes, the panel is performed in a DHA-licensed facility (License 1143) accredited to ISO 9001:2015. Most UAE insurers reimburse this test. Our team handles direct billing verification via WhatsApp at +971 54 548 8731 before sample collection to ensure a smooth claims process.

4. What clinical information does the IHC Digital Panel 4 provide for my treatment plan?

A: The panel determines estrogen receptor (ER) and progesterone receptor (PR) status, HER2/neu amplification status, and Ki-67 proliferation index. These four biomarkers stratify breast cancer into molecular subtypes that guide anti-hormonal therapy, anti-HER2 targeted therapy, and chemotherapy decisions. Results are delivered as a quantitative digital pathology report with standardized scoring.

UAE Regulatory & Data Privacy Adherence

All patient data and clinical information are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genomic and clinical data are encrypted, access-controlled, and never shared with third parties without explicit written consent.

Clinical & Logistical Metadata

Test Name	Immunohistochemistry (IHC) Digital Breast Cancer Panel 4 (ER, PR, HER2, Ki-67)
Price (AED)	1500 AED
Turnaround Time	5–7 working days
Sample Type / Matrix	Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block / Histopathology Slides. Secure Medical Courier Solid Tissue Specimen Retrieval.
Methodology Used	Immunohistochemistry with digital whole-slide imaging and quantitative image analysis
ICD-10-CM Code	C50.9
LOINC Code	85319-2
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE